Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
83% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. PBYI: No Debt )
PBYI' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
84% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
PBYI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 123.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -80.47
PBYI's ROE (%) is ranked higher than
62% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. PBYI: -80.47 )
PBYI' s 10-Year ROE (%) Range
Min: -81.13   Max: -37.64
Current: -80.47

-81.13
-37.64
ROA (%) -68.35
PBYI's ROA (%) is ranked higher than
60% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. PBYI: -68.35 )
PBYI' s 10-Year ROA (%) Range
Min: -1700   Max: -36.94
Current: -68.35

-1700
-36.94
ROC (Joel Greenblatt) (%) -6201.50
PBYI's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. PBYI: -6201.50 )
PBYI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6890.33   Max: -2978.59
Current: -6201.5

-6890.33
-2978.59
EPS Growth (3Y)(%) 883.00
PBYI's EPS Growth (3Y)(%) is ranked higher than
100% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. PBYI: 883.00 )
PBYI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 883
Current: 883

0
883
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

PBYI Guru Trades in Q1 2014

Pioneer Investments 30,901 sh (New)
Jim Simons 12,600 sh (New)
Steven Cohen 78,938 sh (+1261%)
» More
Q2 2014

PBYI Guru Trades in Q2 2014

Steven Cohen 327,900 sh (unchged)
Pioneer Investments Sold Out
Jim Simons Sold Out
» More
Q3 2014

PBYI Guru Trades in Q3 2014

Jim Simons 30,200 sh (New)
RS Investment Management 92,188 sh (New)
Steven Cohen Sold Out
» More
Q4 2014

PBYI Guru Trades in Q4 2014

RS Investment Management Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 45.32
PBYI's P/B is ranked higher than
57% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. PBYI: 45.32 )
PBYI' s 10-Year P/B Range
Min: 0   Max: 51.1
Current: 45.32

0
51.1
Current Ratio 5.45
PBYI's Current Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. PBYI: 5.45 )
PBYI' s 10-Year Current Ratio Range
Min: 0.67   Max: 91.42
Current: 5.45

0.67
91.42
Quick Ratio 5.45
PBYI's Quick Ratio is ranked higher than
78% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. PBYI: 5.45 )
PBYI' s 10-Year Quick Ratio Range
Min: 0.67   Max: 91.42
Current: 5.45

0.67
91.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 51.96
PBYI's Price/Net Cash is ranked higher than
75% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. PBYI: 51.96 )
PBYI' s 10-Year Price/Net Cash Range
Min: 4.69   Max: 58.19
Current: 51.96

4.69
58.19
Price/Net Current Asset Value 51.46
PBYI's Price/Net Current Asset Value is ranked higher than
73% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. PBYI: 51.46 )
PBYI' s 10-Year Price/Net Current Asset Value Range
Min: 4.39   Max: 57.63
Current: 51.46

4.39
57.63
Price/Tangible Book 45.32
PBYI's Price/Tangible Book is ranked higher than
61% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. PBYI: 45.32 )
PBYI' s 10-Year Price/Tangible Book Range
Min: 4.18   Max: 50.76
Current: 45.32

4.18
50.76
Earnings Yield (Greenblatt) -1.80
PBYI's Earnings Yield (Greenblatt) is ranked higher than
82% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. PBYI: -1.80 )
PBYI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.2   Max: 0
Current: -1.8

-2.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PB.Germany,
Puma Biotechnology Inc, a Delaware corporation was incorporated on April 27, 2007. The Company is a development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of advanced breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of advanced cancer patients; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive worldwide rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company has modified Pfizer's clinical development strategy and during the next 12 to 18 months plan to: commence Phase III clinical trials evaluating the use of with HER2-positive metastatic breast cancer who have previously failed two or more prior treatment; continue the ongoing Phase II clinical trial of neratinib in the neoadjuvant treatment of HER2 positive breast cancer, in patients with HER2 positive metastatic breast cancer that has metastasized to the brain; and continue to evaluate the application of neratinib in the treatment of other forms of HER2 positive cancers where there may be unmet medical needs. The Company's competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.
» More Articles for PBYI

Headlines

Articles On GuruFocus.com
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 

More From Other Websites
Who Might Buy Puma Biotechnology? Feb 27 2015
Puma Biotechnology to Present at Cowen Health Care Conference Feb 24 2015
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare... Feb 18 2015
Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare... Feb 18 2015
One ETF Gets a Lift From Rosetta Genomics Feb 17 2015
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology,... Feb 10 2015
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Feb 09 2015
Puma Biotechnology to Present at Leerink Global Healthcare Conference Feb 05 2015
Puma Biotechnology to Present at Leerink Global Healthcare Conference Feb 05 2015
Puma Biotechnology Closes $218 Million Public Offering of Common Stock Jan 27 2015
Puma Biotechnology Closes $218 Million Public Offering of Common Stock Jan 27 2015
Coverage initiated on Puma Biotech. by RBC Capital Mkts Jan 23 2015
Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares Jan 22 2015
Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares Jan 22 2015
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 22 2015
Puma Biotechnology Prices Public Offering of Common Stock Jan 21 2015
Puma Biotechnology Prices Public Offering of Common Stock Jan 21 2015
5 Biotech Secondaries Traders Are Watching Jan 21 2015
Puma Biotechnology Announces Proposed Public Offering Jan 20 2015
Puma Biotechnology Announces Proposed Public Offering Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK